{
  "docId": "019de073-a38b-741c-ac33-1ee77869cf6c",
  "docSlug": "1556a4546991601fbfe098864d52433b",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 36,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline diagram to illustrate the clinical trial flow and two boxes to detail study design and operational status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a38b-741c-ac33-1ee77869cf6c/17",
  "deckHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c",
  "deckJsonHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c.json",
  "deckAnchorHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "diagram",
      "text": "Timeline showing Day -1, 1 (In-clinic dosing), 2, ~8, ~15",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1f6a341-32ec-4f0d-8831-ba90127be68d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.51,
        "y": 0.53
      },
      "kind": "list",
      "text": "Other Important Items: Data expected end of 2022, multi-site US/EU, Phase 1 bioequivalence study, Phase 1 DDI study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5a0cc52-dc8a-4174-abf5-6e1b4ee55428",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.07,
        "y": 0.53
      },
      "kind": "list",
      "text": "Design Overview: 93 subjects, Placebo vs 30/60mg IV, MADRS at 24h, CADSS safety readout",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca68adcd-21cc-4446-98b4-12a9dda1a26f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Note: DDI = Drug-Drug Interaction",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cc9f42d-fcac-400a-9beb-4f7f5da641c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Randomized Phase 2 study of PCN-101 expected to establish human proof-of-concept",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94d40a02-c87b-46f3-b579-41575d9ef455",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "af28e353-2ada-4896-ae80-a66e5a8c9e5e",
      "evidence": "Timeline visualization of clinical trial phases",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}